Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. Hellyer JA, Aredo JV, Das M, Ramchandran K, et al. J Thorac Oncol 2021;16:868-872.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hellyer JA, Aredo JV, Das M, Ramchandran K, et al. Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. J Thorac Oncol 2021;16:868-872.
PMID: 33539970